ProKidney Corp. (PROK) Stock Ticker
PROK right now
Market factors today
Unlock the full PROK picture
About ProKidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK stock facts
| Ticker symbol | PROK |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $538.0M |
| CEO | Bruce Culleton |
| Employees | 231 |
| Headquarters | Winston-Salem, NC, US |
| IPO date | 2021-06-30 |
| Website | www.prokidney.com |
What you can see for PROK on Tickr
Live PROK price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PROK report.
Rankings
FAQ
What is the ticker symbol for ProKidney Corp.?
The ticker symbol for ProKidney Corp. is PROK, listed on the NASDAQ Capital Market.
What is PROK?
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals…